Related Experiment Video
Updated: Mar 21, 2026
Intratracheal Instillation of Stem Cells in Term Neonatal Rats
Published on: May 4, 2020
Mesenchymal stromal cells in the development and therapy of bronchopulmonary dysplasia
Marius A Möbius1,2,3, Mario Rüdiger4,5
1Department of Neonatology and Pediatric Critical Care Medicine, Medical Faculty and University Hospital Carl Gustav Carus, Technische Universität Dresden, Fetscherstrasse 74, Dresden, 01307, Germany. Marius.Moebius@uniklinikum-dresden.de.
Insights
Mesenchymal stem cells (MSCs) show promise for treating bronchopulmonary dysplasia (BPD), a chronic lung disease in premature infants. Further research is needed to understand MSC mechanisms and manufacturing for effective BPD therapies.
Area of Science:
- Neonatology
- Pulmonology
- Stem Cell Biology
Background:
- Bronchopulmonary dysplasia (BPD) is a significant chronic lung disease affecting premature infants, with no current cure.
- Complex pathophysiology hinders effective treatment development for BPD.
- Recent advances in understanding mesenchymal stem cells (MSCs) offer potential therapeutic avenues for BPD.
Purpose of the Study:
- To review the role of resident and exogenous MSCs in lung development.
- To summarize the potential of MSCs in preventing and treating BPD.
- To highlight the current status of MSC-based therapies for BPD.
Main Methods:
- Literature review of pre-clinical studies on MSCs and BPD.
- Summary of early-phase clinical trials involving MSCs for BPD.
- Discussion of MSC mechanisms of action and manufacturing considerations.
Main Results:
- Pre-clinical studies demonstrate promising results for MSCs in BPD models.
- Early clinical trials are underway to evaluate MSC efficacy and safety.
- Understanding MSC mechanisms and manufacturing is crucial for therapeutic development.
Conclusions:
- MSCs represent a hopeful strategy for BPD prevention and treatment.
- Ongoing research and clinical trials are essential to realize the therapeutic potential of MSCs.
- Further investigation into MSC biology and production is required for clinical application.
Abstract:
Bronchopulmonary dysplasia (BPD), the chronic lung disease of prematurity, remains a major healthcare burden. Despite great progresses in perinatal medicine over the past decades, no cure for BPD has been found. The complex pathophysiology of the disease further hampers the development of effective treatment strategies, but recent insights into the biology of mesenchymal stem (MSCs) and progenitor cells in lung development and disease have ignited the hope of preventing or even treating BPD. The promising results of pre-clinical studies have lead to the first early phase clinical trials. However, these treatments are experimental and much more needs to be learned about the mechanism of action and manufacturing of MSCs. In this mini review, we briefly summarize the role of resident and exogenous MSCs in the development and treatment of BPD.
Related Concept Videos
01:19Mesenchymal Stem Cells
01:21Stem Cell Therapy for Tissue Regeneration
Types of Stem Cells used in Stem Cell Therapy
The two main cell...